The drug has been previously approved in Europe for the treatment of cystic fibrosis patients ages 12 months and older.
The marketing clearance is subject to final approval by the European Commission.
Shares were little changed before midday.
Price: 177.27, Change: -0.45, Percent Change: -0.25
|Earnings Projection for Zynex in 2021 Bumped Up|
|2020, and 2021 Earnings Estimates for Zscaler Scaled Up|
|Joyy Inc's 2021 Earnings Forecast Lowered|
|Consensus for Yandex NV 2020 Earnings Decreased but ...|
|Consensus for Williams Sonoma Q2 and 2022 Forecast P...|